Aims: Circulating microRNAs (miRNAs) as biomarkers for leukemia have been validated by emerging studies. This meta-analysis aims to estimate the overall diagnostic accuracy of bloodbased circulating miRNAs for leukemia. Methods: We searched multiple databases (PubMed, EMBASE, Cochrane Library, CNKI, Wan Fang Data and CQVIP) up to June 18, 2015. Results: 32 studies from 10 publications were included in this meta-analysis. Diagnostic capacity was evaluated by pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the curve (AUC) through randomeffects model. Sensitivity analyses were sequentially performed to find potential sources of heterogeneity. The quality of included studies was assessed by QUADAS (quality assessment for studies of diagnostic accuracy). Meta-Disc 1.4 and Stata 12.0 software were used to perform the meta-analysis. A high diagnostic accuracy was displayed, with a sensitivity of 0.84, a specificity of 0.88, a PLR of 7.20, a NLR of 0.18, a DOR of 52, and an AUC of 0.94. Subgroup analyses revealed better performance for combined miRNAs, acute myeloid leukemia patients and Asian population than other subgroups. Conclusion: Our analyses suggested that bloodbased circulating miRNAs are promising diagnostic biomarkers for leukemia, especially combined miRNAs. Its clinical application awaits further study.
Introduction
Leukemia is a highly heterogeneous hematopoietic cancer, characterized by the accumulation of immature cells and disturbed hematopoiesis in bone marrow. Every year, over 250,000 individuals worldwide are diagnosed with leukemia, which includes four major categories: acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia [1] . Significant improvements in diagnosis and treatment of leukemia have been presented in the last decades, thanks to MICM (morphology, immunology, cytogenetic, molecular) diagnostic classification for leukemia since 2001 [2, 3] . At the same time, the overall incidence rate of leukemia is still on the rise (by 0.5% per year) [4] . The current MICM has contributed to personalized treatment and prognostic evaluation of leukemia, but it is hyposensitive, costly, and invasive, with a complex process of bone marrow extraction. Thus, novel noninvasive biomarkers for diagnosis and classification of leukemia are desperately needed.
MicroRNAs (miRNAs) are a family of short, single strand and non-coding RNAs (~22nt), which target over 30% of human genes [5] . Disturbance of miRNA expression can contribute to the multistep processes of carcinogenesis [6, 7] . Circulating miRNAs are a class of miRNAs originating from tissues and appearing in the cell-free body fluids (e.g. plasma, serum, urine, saliva, etc.). Their notable characteristics such as ease of access, high stability increase their potential as diagnostic, prognostic, and predictive biomarkers of the disease [8] [9] [10] . A recent research has indicated that disturbing expression of circulating miR-200c was significantly associated with the outcome in cancer patients [11] . In 2008, three studies covered the field on circulating miRNAs at the same time [8, 12, 13] , which prompted the investigation on circulating miRNAs as novel and minimal invasive biomarkers of cancers. The first reported blood-based circulating miRNA was miR-21, which aberrantly expressed in serum of patients with diffuse large B-cell lymphoma [14] . Since then, increasing studies have identified growing number of circulating miRNAs as potential diagnostic biomarkers for leukemia [15] [16] [17] [18] .
However, many discrepancies are presented among these findings. Xie et al. first reported the up-regulation of serum miR-155 in patients with AML, with a diagnostic accuracy of sensitivity 69% and specificity 88% [19] . Subsequently, Zhi et al. also examined circulating miR-155 in AML patients but reached at relatively higher sensitivity and specificity of 90% and 96%, respectively [18] . This inconsistency awaits more interpretation. Furthermore, another study examined the performance of two miRNAs (miR-150 and miR-155) in distinguishing acute leukemia (AL) from healthy controls, and found that their combination had a higher diagnosis accuracy than single ones [20] . In addition, Ohyashiki et al. found that the diagnostic accuracy of miR-92a was significantly elevated using cell to plasma ratio of miR-92a in patients with AL [21] . These findings suggest that miRNAs in peripheral blood as diagnostic biomarkers for leukemia is desirable under certain improvements. Differences among studies need further systematic evaluation. Hence, we performed the present metaanalysis, to provide an up-to-date and comprehensive assessment on the overall diagnostic accuracy of blood-based circulating miRNAs for leukemia.
Material and Methods

Search strategy and study selection
We performed comprehensive search in diverse databases, including the PubMed, Cochrane library, EMBASE, Chinese National Knowledge Infrastructure (CNKI), Wan Fang Data and Technology of Chongqing databases (CQVIP) until June18, 2015, but without a lower date and language limit. The search terms were "microRNA or miRNA or has-miR", "circulating or serum or sera or plasma or peripheral blood", "leukemia or hematological malignancy/cancer/ tumor/carcinoma/neoplasms", and "diagnosis or sensitivity or specificity or ROC curve". In addition, to identify additional information, we also reviewed the references list in retrieved studies, and even contacted authors if necessary.
Further inclusion criteria for the meta-analysis were as follows: (1) clinical studies on evaluation of blood-based circulating miRNAs in diagnosis of leukemia; (2) studies presenting complete data to allow construction of fourfold table; (3) studies using healthy individuals as controls; (4) original research papers. The exclusion criteria included: (1) studies without sufficient data; (2) unqualified data; (3) duplicate publication; (4) studies with patients less than 20. Study eligibility was assessed independently by two reviewers (Lihua Xu and Yang Guo). Another reviewer (Xueli Zhang) also joined in data extraction. Any disagreements were resolved under full discussion with the third reviewer.
Data extraction and quality assessment Two independent reviewers screened literatures for the following data: first author, year of publication, ethnicity, disease type, sample size, specimen source, miRNAs profile, test method, sensitivity and specificity. Quality Assessment of Diagnostic Accuracy Studies (QUADAS) checklist was employed to evaluate the quality of included studies [22] .
Statistical analysis
According to the guidelines for diagnostic accuracy meta-analysis [23] , we extracted accuracy data from each study, including true positives (TP), false positives (FP), true negatives (TN), and false negatives (FN). Sensitivity, specificity, positive likelihood ratio (PLR), and negative likelihood ratio (NLR) were calculated to evaluate the ability to distinguish leukemia patients from the healthy controls. Diagnostic odds ratio (DOR) and area under the curve (AUC) of the summary receiver operator characteristic (SROC) curve were used to assess overall performance of each diagnostic test. The heterogeneity among studies was assessed by index (I 2 ) of pooled DOR. I 2 value > 50% indicated the existence of heterogeneity. Statistical analyses were performed by Meta-Disc version 1.4 software [24] and Stata version 12.0 (Stata Corporation, College Station, TX, USA). All statistical tests were two sided, with significance set at p<0.05. Deeks' funnel plot was used to identify potential publication bias.
Results
Quality and characteristics of included studies
The study selection flowchart is showed as Fig. 1 . A total of 384 articles were retrieved through the above database (n = 378) and other sources (n = 6). 320 articles were excluded on the basis of title and abstract. The full texts of the remaining 64 articles were carefully screened and 54 articles failing to meet the inclusion criteria were excluded. Finally, ten highquality articles were used in this meta-analysis, of which, three were on AL (not separated clearly for ALL or AML), five were on AML, two were on CLL. Ten articles contained 32 studies which were all brought into our analyses [15] [16] [17] [18] [19] [20] [21] [25] [26] [27] , including 554 patients with leukemia and 409 healthy controls. The main information of included studies was listed in Table 1 . The QUADAS scores ranged from 10 to 13, suggesting high quality of the included studies.
Diagnostic accuracy analysis
Forest plot of sensitivity and specificity for blood-based circulating miRNA in the diagnosis of leukemia were showed in Fig. 2 . The summary estimates for diagnostic accuracy were listed in Table 2 . Pooled sensitivity, specificity, PLR, and NLR were 0.84, 0.88, 7.20, 0.18 ( Fig. 2a-d) , respectively, which revealed that circulating miRNAs were great biomarkers for diagnosis of leukemia. Overall diagnostic accuracy was assessed by the pooled DOR (Fig. 2e) and AUC (Fig.  2f) . Their values were 52 and 0.94, respectively, suggesting a high diagnostic accuracy. Nevertheless, the I 2 value of pooled DOR was 75.7%, which indicated a high heterogeneity among 32 studies. Therefore, we selected a Random-effects Model throughout the meta-analysis, and performed a series of sensitivity analysis (threshold effect, meta-regression and subgroup analyses) to seek the sources of heterogeneity.
Analysis diagnostic threshold effect
The threshold effect is a pivotal source of heterogeneity in diagnostic tests. It is caused by differences in the sensitivity and specificity. One good way to assess the threshold effect is Spearman correlation coefficient of sensitivity and specificity [24] . Our analyses showed that Spearman correlation coefficient in total 32 studies was-0.04 (P = 0.83), indicating that the heterogeneity was not caused by threshold effect. suggested a 4.94 fold higher diagnostic accuracy for combined miRNAs (i.e. miRNA panels) than single ones. After excluding seven studies on single miRNA that only appears once in included studies with lower sensitivity, the overall heterogeneity (I 2 value) decreased from 75.7% to 45.4% for DOR. 
Subgroup analyses
Further subgroup analyses also indicated that the diagnostic accuracy was better for combined miRNAs than single ones, with a sensitivity of 0.92, a specificity of 0.93, a PLR of 11.53, a NLR of 0.10, a DOR of 165, and an AUC of 0.97 (Table 2 , Fig. 3a) . Moreover, acute myeloid leukemia (AML) patients displayed a better performance than other subgroups, with DOR of 51 and an AUC of 0.94 (Fig. 3b) . A higher diagnostic value was also found in Asian population compared to European population, with a DOR of 61 and an AUC of 0.94 (Table 2 , Fig. 3c ). In addition, serum miRNAs have moderately better diagnostic accuracy than plasma miRNAs for leukemia, with a pooled sensitivity of 0.86 and an AUC of 0.94 (Fig. 3d) . Even on the premise of keeping homogeneity, the diagnostic accuracy for remaining 25 studies is still superb (Fig. 4a-d) .
Publication Bias
The publication bias of included studies was checked by Deeks' funnel plot asymmetry test, and the result is shown as Fig. 5 . A statistically non-significant value (p = 0.75) in the funnel plot indicated no potential publication bias, regardless of slight asymmetry due to the small number of publications.
Discussion
Leukemia contributed 2.5% to the overall cancers incidence [1] . Non-invasive and convenient methods for the early detection of leukemia could greatly decrease the worldwide health burden [28] , and will be of very useful clinical significance. In the present study, we performed a systematic review pointed to studies related to blood-based circulating miRNAs expression in leukemia. We displayed the most potentially effective candidate circulating miRNAs in diagnosing leukemia, with 14 up-regulated and 6 down-regulated miRNAs, as well as 9 miRNAs combinations. However, it must be noted that significant heterogeneity existed in the data of included studies, which was most likely attributable to the miRNA profile. Subgroup analyses demonstrated that combined miRNA panels were promising biomarkers for leukemia with superb diagnostic accuracy. In addition, AML patients and Asian population presented moderately better performance than other subgroups, respectively. As far as we know, this is the first meta-analysis specially focusing on circulating miRNAs in leukemia, with comprehensively and systemically quantitative evaluation on the diagnostic value.
Circulating miRNAs are packaged inside microvesicles (e.g. exosomes) secreted from cancer cells, and function in new location by being delivered from one cell to another [29, 30] . These might be a class of effective and stable biomarkers, and can be quantitatively measured by qRT-PCR. Kroh et al. [31] have summarized the procedure for qRT-PCR analysis of blood-based circulating miRNAs, which produce increasingly standardized investigation on circulating miRNAs. Since then, circulating miRNAs have attracted a great deal of attention as novel, minimally invasive biomarkers for various diseases. Recently, Li et al. [32] reviewed the publications on circulating miRNAs as diagnostic biomarkers in overall hematologic cancers, and found a better diagnostic accuracy for AML than other cancers in hematopoietic system.
In current meta-analysis, we thoroughly searched multiple databases and retrieved 32 studies aimed at circulating miRNAs for whole leukemia. Analysis showed that blood-based circulating miRNAs has a relatively high diagnostic accuracy in leukemia, with a pooled sensitivity of 0.84, specificity of 0.88. Moreover, a PLR value of 7.2 indicated a moderate ability of circulating miRNAs assays in discriminating leukemia patients from normal individuals, and a NLR value of 0.18 also shows a moderate ability to exclude patients without leukemia. Furthermore, DOR value and SROC curve are indexes for overall accuracy. An effective DOR value should be greater than 1, and higher values suggest better test discrimination [33] . The position of ideal SROC curve is near the upper-left corner, indicating a perfect test [34] . In this meta-analysis, the overall pooled DOR was 52, and AUC of the SROC curve was 0.94, which suggested an excellent diagnostic accuracy of circulating miRNA in leukemia. However, the I 2 value of global DOR > 50%, revealing a significant heterogeneity. It is an inevitable issue when interpreting the results for meta-analysis. To explore the potential sources of heterogeneity, we carried out sensitivity analyses. The results of threshold effect and Meta regression analyses showed obvious heterogeneity not caused by threshold (p=0.83), but originating from miRNAs profile. Then we further searched all the included studies, and found seven studies with lower sensitivity all focused on single miRNA that only appeared once in the included studies. After excluding these seven studies from five publications [16] [17] [18] [19] 26] , the heterogeneity (I 2 value) decreased from 75.7% to 45.4% for DOR. Subgroup analyses were conducted according to the classification of disease, miRNAs profile, specimen and ethnicity. Based on miRNAs profile, we showed that combined miRNAs as diagnostic biomarkers for leukemia are more promising, compared to single miRNA, which is consistent with previous studies. Zhou [20] demonstrated that combining miR-150 and miR-155 could be a more powerful diagnostic biomarker for distinguishing AL patients from normal individuals, with a sensitivity of 91.4 % and specificity of 87.5 % than either a single miR-150 with a sensitivity of 77.1% and specificity of 87.5%, or a single miR-155 with a sensitivity of 88.6 % and specificity of 62.5 %. Besides, the results of Moussay et al. also showed that single miRNAs (miR-195, miR-222, or miR-29a) may help rule out individuals without CLL, with 100% specificity, but a better diagnostic accuracy was obtained by the combination of the three miRNAs with increased sensitivity of 90.2% in the case of specificity unchanged [16] . Moreover, we showed that AML subgroup had a better diagnostic value than other subgroups, similar to the earlier studies. Huang et al. [25] investigated 26 AML patients and 26 healthy controls, revealing that circulating miR-335 was a useful diagnostic biomarker for AML with 80.8% sensitivity and 100% specificity. In the study from Xie et al. [19] , a high diagnostic value for discriminating AML was present at either single miRNA (miR-21, miR-210, or miR-221) or their combination. In addition, as for ethnicity, it has been reported there existed race-based differences in the amount of circulating miRNAs [32, 35, 36] . We also found higher DOR and AUC value in Asian population compared to European populations (61 versus 21 and 0.94 versus 0.85, respectively), indicating better accuracy of blood-based circulating miRNAs assays in Asian populations. Taken together, our subgroup analyses showed excellent overall accuracy in miRNAs combination, AML, and Asian subgroup compared to others, which is consistent with the meta-analysis on entire hematological cancers by Li and his colleagues [32] . However, as to the specimen, although both plasma and serum had high diagnostic accuracy in our results, we failed to find an obvious difference between plasma and serum, which is different from the previous studies. McDonald et al. found higher miRNAs concentrations in plasma compared to serum [37] , while Li et al. showed a better performance of plasma miRNA assay in diagnosing hematopoietic cancers [32] . In our results, the AUC of serum-based miRNA assays are greater than that of plasmabased miRNA assays (0.94 versus 0.91). In this respect, the overall diagnostic accuracy of serum should be better than plasma, if regardless of the slightly higher DOR in plasma compared to serum (54 versus 49). The two studies on Asian may be able to explain some problems. Chen et al. [13] found that the serum-based miRNAs can keep good concordance with blood cell miRNAs, and Zhang et al. [38] showed no significant difference between plasma miRNAs and serum miRNAs. Thus, to reach at a trade-off, future study should give more attention to the sample source of circulating miRNAs.
Compared to the previous studies, the present meta-analysis has several advantages. Firstly, the objective of this analysis is leukemia's circulating miRNAs. As the first metaanalysis specifically directed at the diagnostic value of circulating miRNAs in leukemia, its results are very encouraging and promising. Secondly, we included more studies on circulating miRNAs by conducting thoughtful search terms to find emerging literatures in recent years. It enhances the reliability of our evaluation on overall diagnostic value of miRNA assay. In addition, we employed Meta-Disc software to quantitatively analyze the previous individual studies. Meta-Disc is a comprehensive and special software for diagnostic metaanalysis and has already been cited in many high-quality meta-analyses, demonstrating the excellent performance of this software [24] . Nevertheless, our meta-analysis still has certain limitations. First, as the value of circulating miRNAs as diagnostic biomarkers has been explored only in recent years, sample sizes have been small, e.g. the study of FayyadKazan et al. [17] included only 20 AML patients. As a result, a small-study effect might be presented. Second, because of relatively fewer studies and smaller sample sizes, subgroup classification on sex, age, and subtype of leukemia, has not been considered in this analysis. Yet these factors are closely associated with the development, progression, and prognosis of certain leukemias [3] . The third, there is no consensus on the endogenous reference for circulating miRNA quantification. Although the detection for circulating miRNAs is all based on qRT-PCR in our studies, different laboratories might take different endogenous controls to quantify circulating miRNAs, which can also contribute to sources of heterogeneity. For example, Fayyad-Kazan et al. selected miR-16, while Tanaka et al. used miR-683 as internal control, since circulating miR-16 and miR-638 have been identified stably and consistently either in patients or in normal individuals [15, 17] . Unfortunately, most of included studies did not mention the details about the internal control. Finally, our analyses have not covered the functions of circulating miRNAs in ALL and CML, due to absence of eligible studies on these two subtypes.
The current meta-analysis suggested a potential value of blood-based circulating miRNA for diagnosis of leukemia. Through subgroup analysis, we showed better performance in
